Heteroresistance to colistin in oxacillinases-producing carbapenem-resistant Acinetobacter baumannii clinical isolates from Gorgan, Northern Iran.
Colistin resistance rates are arising worldwide among the multidrug-resistant Gram-negative bacilli, including Acinetobacter baumannii. A new type of resistance, heteroresistance, has also been reported to colistin in clinical A. baumannii isolates. This study investigated the presence of colistin heteroresistance in carbapenem-resistant A. baumannii clinical isolates. Different clinical specimens from the hospitalized patients were investigated for A. baumannii. MICs to imipenem, meropenem, and colistin were determined by broth microdilution. PCR was performed for detection of OXA-type carbapenemase genes (blaOXA-23-like, blaOXA-24/40-like, blaOXA-51-like, blaOXA-58-like, and blaOXA-143-like). Heteroresistance to colistin was examined using population analysis profiles (PAPs) method. Genotypic relatedness of the isolates was analyzed by enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR). Overall, 71 isolates of A. baumannii were recovered from clinical specimens. Of these, 38.03% (n = 27) and 61.97% (n = 44) were carbapenem-susceptible and carbapenem-resistant, respectively. In addition, 94.36% (67/71) of isolates were susceptible to colistin with MIC between 0.25 and 2 µg/mL. Among the 44 selected carbapenem-resistant, colistin-susceptible isolates, the frequency of blaOXA-51-like, blaOXA-23-like, and blaOXA-24/40-like genes was 100%, 77.27%, and 43.18%, respectively. The 20.45% of isolates (n = 9/44) were characterized as colistin-heteroresistant with subpopulations growing at 6-8 μg/mL, whereas 4.54% (n = 2/44) presented heterogeneous subpopulations growing at up to 1 μg/mL of colistin. ERIC‑PCR typing clustered A. baumannii isolates to 10 common types (CT1-CT10) containing isolates from different hospitals and 12 single types (ST1-ST12). Importantly, A. baumannii with colistin heteroresistance phenotype was common. This could be a great concern, since that colistin is often used as a last-resort drug for treatment of A. baumannii infections, highlighting the care is necessary with colistin monotherapy. In addition, more effective strategy and surveillance are required to confine and prevent the inter- and/or intra-hospital dissemination of A. baumannii between our therapeutic centers.